Kailera Therapeutics (NASDAQ:KLRA) Stock Crosses Above 50-Day Moving Average – Should You Sell?

Posted by Brian Himes on Nov 7th, 2026

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA – Get Free Report) passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $12.78 and traded as high as $13.26. Kailera Therapeutics shares last traded at $12.97, with a volume of 733,039 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.75.

Check Out Our Latest Research Report on KLRA

Kailera Therapeutics Stock Performance

The firm has a market cap of $1.68 billion and a PE ratio of -0.00. The firm has a 50 day moving average of $12.78.

Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.81. As a group, equities analysts predict that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Hedge Funds Weigh In On Kailera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Commonwealth Equity Services LLC purchased a new position in Kailera Therapeutics in the third quarter valued at about $134,000. Tidal Investments LLC bought a new stake in Kailera Therapeutics during the 2nd quarter worth approximately $309,000. Profund Advisors LLC bought a new position in shares of Kailera Therapeutics in the third quarter valued at $216,000. Alps Advisors Inc. raised its position in Kailera Therapeutics by 31.1% during the 3rd quarter. Alps Advisors Inc. now owns 171,739 shares of the company’s stock worth $1,961,000 after purchasing an additional 40,739 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Kailera Therapeutics during the 2nd quarter valued at $993,000.

Kailera Therapeutics Company Profile

(Get Free Report)

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.